Slide background
Slide background




Safe design and operation of on site generation of oxygen 93% for medical use

ID 1668 | | Visite: 5168 | Documenti Chemicals EntiPermalink: https://www.certifico.com/id/1668



Safe design and operation of on site generation of oxygen 93% for medical use

Oxygen for medicinal use is a prime requirement for all healthcare facilities for both the treatment of patients with respiratory disease and for providing additional oxygen to patients being treated within the facility.

For those hospitals and clinics, where the demand is higher, oxygen is normally distributed throughout the facility using a medical gas pipeline system.

The design requirements for the supply source used to supply medical oxygen to the pipeline system are detailed in the standard, EN ISO 7396-1 Medical gas pipeline systems; Pipeline systems for compressed medical gases and vacuum.

Two different products are included in the standard:

- Medicinal oxygen supplied from liquid oxygen vessels and/or gaseous oxygen cylinders; and
- Oxygen 93 manufactured on-site within the healthcare facility, using an oxygen concentrator unit.

Medicinal oxygen supplied either in cylinders or as a cryogenic liquid, is required to be manufactured by an approved supplier with a manufacturers licence (to demonstrate compliance with guidelines detailed in the European Commission’s Guide to Good Manufacturing Practice (GMP))

Within the European Union, the supplier of medical oxygen is required to hold a marketing authorisation in accordance with Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use, detailing the clinical indications and contraindications and specific warnings for the safe use of the product.

The specification of this medical oxygen is detailed in the European Pharmacopoeia monograph for medical oxygen, which specifies a minimum purity of 99.5% oxygen.

The quality, safety and efficacy of the medical oxygen are ensured by the medical gas supplier through a quality management system under the responsibility of a qualified person.

Oxygen 93 can be manufactured on-site within the healthcare facility, under the responsibility of the healthcare facility pharmacist, using an oxygen 93 supply system and meeting the appropriate and specific quality and safety criteria for medicinal products prepared in Pharmacies (see Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme Guide PE010-4 Guideline to good practices for the preparation of medicinal products in healthcare establishment).

Oxygen 93 is not being ‘put on the market’, so it currently falls outside the regulation for the manufacture and supply of medicinal product Directive 2001/83/EC.

Oxygen 93 concentrator units are covered by the requirements for CE marking in accordance with the Medical Device Directive, (Council Directive 93/42/EEC of 14 June 1993 concerning medical devices).

The specification of the oxygen manufactured using an oxygen 93 supply system is detailed in the European Pharmacopoeia monograph for oxygen 93, which specifies the oxygen content to be between 90% and 96% and gives appropriate limits and analysis methods of other possible contaminants during the production.

As the oxygen 93 is produced by adsorbing the nitrogen from ambient air, the major contaminant in oxygen 93 is argon, which can be present up to 5%.

When the oxygen 93% monograph was introduced it was stated that the benefits of PSA oxygen (oxygen 93 per cent) are to allow production and supply of oxygen at sites where access for cylinder and liquid oxygen supply is difficult or impossible. PSA concentrators are in use in a number of fields particularly by the military (field hospitals).

The quality of the gas is very much dependent upon the performance of the equipment that produces it.

At the time of preparation of this publication, oxygen 93 is not licensed under a marketing authorisation, thus it is not evaluated by regulatory authorities and thus it cannot be considered as “equivalent medicine” for the oxygen.

EIGA 2015

Descrizione Livello Dimensione Downloads
Allegato riservato Safe Design and Operation On Site Generation Oxygen 93 for Medical Use.pdf
EIGA 2015
291 kB 13

Tags: Chemicals EIGA

Articoli correlati

Ultimi archiviati Chemicals

Giu 24, 2022 34

Regolamento (UE) 2021/2142

Regolamento (UE) 2021/2142 Regolamento (UE) 2021/2142 della Commissione del 3 dicembre 2021 che modifica il regolamento (CE) n. 1881/2006 per quanto riguarda i tenori massimi di alcaloidi oppiacei in alcuni prodotti alimentari. (GU L 433 del 6.12.2021) Collegati[box-note]Regolamento (CE) n.… Leggi tutto
Faster action on groups of harmful chemicals
Giu 17, 2022 73

ECHA - Integrated Regulatory Strategy (IRS) Annual Report 2021

ECHA - Integrated Regulatory Strategy (IRS) Annual Report 2021 Faster action on groups of harmful chemicals - Integrated Regulatory Strategy Annual Report June 2022 Helsinki, 17 giugno 2022 È stato pubblicato il quarto rapporto dell'ECHA nell'ambito della sua strategia di regolamentazione… Leggi tutto
Mag 31, 2022 94

Decreto 11 ottobre 2001

Decreto 11 ottobre 2001 Condizioni per l'utilizzo dei trasformatori contenenti PCB in attesa della decontaminazione o dello smaltimento. (GU n.255 del 02.11.2001) Collegati
D.P.R. 24 maggio 1988, n. 216Decreto Legislativo 22 maggio 1999 n. 209
Leggi tutto
Mag 31, 2022 110

D.P.R. 24 maggio 1988, n. 216

D.P.R. 24 maggio 1988, n. 216 Attuazione della direttiva CEE n. 85/467 recante sesta modifica (PCB/PCT) della direttiva CEE n. 76/769 concernente il ravvicinamento delle disposizioni legislative, regolamentari ed amministrative degli Stati membri relative alle restrizioni in materia di immissione… Leggi tutto
Mag 30, 2022 144

Regolamento delegato (UE) 2022/825

Regolamento delegato (UE) 2022/825 Regolamento delegato (UE) 2022/825 della Commissione del 17 marzo 2022 che modifica l’allegato II del regolamento delegato (UE) n. 1062/2014 relativo al programma di lavoro per l’esame sistematico di tutti i principi attivi esistenti contenuti nei biocidi di cui… Leggi tutto
Mag 30, 2022 100

Regolamento (CE) n. 907/2006

Regolamento (CE) n. 907/2006 Regolamento (CE) n. 907/2006 della Commissione, del 20 giugno 2006, che modifica il regolamento (CE) n. 648/2004 del Parlamento europeo e del Consiglio relativo ai detergenti ai fini di un adeguamento degli allegati III e VII. (GU L 168, 21.6.2006)… Leggi tutto

Più letti Chemicals

Regolamento  CE  n  178 2002
Mar 17, 2022 64804

Regolamento (CE) N. 178/2002

Regolamento (CE) n. 178/2002 Regolamento (CE) n. 178/2002 del Parlamento europeo e del Consiglio del 28 gennaio 2002 che stabilisce i principi e i requisiti generali della legislazione alimentare, istituisce l'Autorità europea per la sicurezza alimentare e fissa procedure nel campo della sicurezza… Leggi tutto